Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Buy
59
ORMP Quote, Financials, Valuation and Earnings
Last price:
$3.54
Seasonality move
:
12.3%
Day range:
$3.34 - $3.47
52-week range:
$1.82 - $3.71
Dividend yield:
7.38%
P/E ratio:
3.38x
P/S ratio:
70.57x
P/B ratio:
0.66x
Volume:
217.8K
Avg. volume:
278.5K
1-year change:
47.39%
Market cap:
$134.9M
Revenue:
--
EPS (TTM):
$1.00
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Oramed Pharmaceuticals, Inc. has -4.13% downside to fair value with a price target of $3.25 per share.
ORMP vs. S&P 500
-
Over the past 5 trading days, Oramed Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oramed Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oramed Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Oramed Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Oramed Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Oramed Pharmaceuticals, Inc. reported earnings per share of $1.13.
Enterprise value:
151.5K
EV / Invested capital:
--
Price / LTM sales:
70.57x
EV / EBIT:
-155.86x
EV / Revenue:
0.08x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-100.77x
Gross Profit (TTM):
-$109K
Return On Assets:
25.77%
Net Income Margin (TTM):
-1211.15%
Return On Equity:
27.49%
Return On Invested Capital:
27.4%
Operating Margin:
-225%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2M | -- | $2M | -- | -- | |
| Gross Profit | $1.2M | -$215K | -$109K | -$52K | -$31K | |
| Operating Income | -$21.6M | -$13.1M | -$13M | -$3.1M | -$2.4M | |
| EBITDA | -$21.5M | -$12.8M | -$12.9M | -$3M | -$2.4M | |
| Diluted EPS | -$0.41 | $0.11 | $1.00 | -$0.48 | $1.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $160.2M | $175.7M | $142.8M | $136.1M | |
| Total Assets | -- | $164.4M | $230.9M | $165.1M | $220.5M | |
| Current Liabilities | -- | $6.5M | $78.2M | $5.3M | $6.1M | |
| Total Liabilities | -- | $11.3M | $82.7M | $9.6M | $18.2M | |
| Total Equity | -- | $153.1M | $148.2M | $155.5M | $202.3M | |
| Total Debt | -- | $672K | $389K | $186K | $589K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.2M | -$7.8M | -$11M | -$7.1M | -$2M | |
| Cash From Investing | -$89.1M | $119.4M | $23.2M | -$33.6M | $38.8M | |
| Cash From Financing | $78.5M | -$75M | -$2.2M | -$1.5M | -$392.6K | |
| Free Cash Flow | -$16.8M | -$7.8M | -$11M | -$7.1M | -$2M | |
ORMP
Sector
Market Cap
$134.9M
$25.9M
Price % of 52-Week High
91.38%
51.6%
Dividend Yield
7.38%
0%
Shareholder Yield
1.75%
-1.66%
1-Year Price Total Return
47.39%
-18.99%
Beta (5-Year)
1.195
0.485
Dividend yield:
7.38%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.51
200-day SMA
Buy
Level
$2.41
Bollinger Bands (100)
Buy
Level
2.25 - 3.05
Chaikin Money Flow
Sell
Level
-50.3K
20-day SMA
Buy
Level
$3.27
Relative Strength Index (RSI14)
Buy
Level
57.31
ADX Line
Neutral
Level
Williams %R
Neutral
Level
-37.6471
50-day SMA
Buy
Level
$2.94
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
217.8K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.0355)
Buy
CA Score
(Annual)
Level (0.7199)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (0.0069)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, ORMP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ORMP average analyst price target in the past 3 months is $3.25.
-
Where Will Oramed Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oramed Pharmaceuticals, Inc. share price will drop to $3.25 per share over the next 12 months.
-
What Do Analysts Say About Oramed Pharmaceuticals, Inc.?
Analysts are divided on their view about Oramed Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oramed Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $3.25.
-
What Is Oramed Pharmaceuticals, Inc.'s Price Target?
The price target for Oramed Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $3.25 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ORMP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oramed Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ORMP?
You can purchase shares of Oramed Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oramed Pharmaceuticals, Inc. shares.
-
What Is The Oramed Pharmaceuticals, Inc. Share Price Today?
Oramed Pharmaceuticals, Inc. was last trading at $3.54 per share. This represents the most recent stock quote for Oramed Pharmaceuticals, Inc.. Yesterday, Oramed Pharmaceuticals, Inc. closed at $3.39 per share.
-
How To Buy Oramed Pharmaceuticals, Inc. Stock Online?
In order to purchase Oramed Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ORMP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ORMP
Sector
P/E ratio
3.38x
23.82x
PEG ratio
0.00x
-0.01x
P/B ratio
0.66x
1.83x
Price / LTM sales
70.57x
1.56x
Growth Metrics
ORMP
Sector
Revenue growth
--
4.18%
Earnings growth
335.86%
9.66%
Revenue (5-year growth)
-100%
6.28%
Earnings forecast
-$0.07
-$0.18
Profitability
ORMP
Sector
Profitability FY 2024
-$193K
$3.1M
Return on invested capital
27.4%
-32.89%
Return on assets
25.77%
-29.56%
Return on equity
27.49%
-38.66%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
12
Balance Sheet
ORMP
Sector
Total cash
$134.7M
$25.2M
Short term investments
$87.5M
$25.1M
Total assets
$155.3M
$73M
Long term debt
$589K
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
70
BNAI alert for Jan 26
Brand Engagement Network, Inc. [BNAI] is up 180.4% over the past day.
Buy
56
INTC alert for Jan 26
Intel Corp. [INTC] is down 5.37% over the past day.
Buy
64
BNR alert for Jan 26
Burning Rock Biotech Ltd. [BNR] is up 2.68% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
